A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single And Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, And Food Effect of RO5024048 [RG 7128] in Healthy Volunteers And in Patients With Chronic HCV [hepatitis C virus] Infection.

Trial Profile

A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single And Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, And Food Effect of RO5024048 [RG 7128] in Healthy Volunteers And in Patients With Chronic HCV [hepatitis C virus] Infection.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2010

At a glance

  • Drugs Mericitabine; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Pharmasset
  • Most Recent Events

    • 13 Apr 2010 Follow-up data from cohort 4 will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver, according to a Pharmasset media release.
    • 25 Apr 2009 Status changed from recruiting to completed, according to ClinicalTrials.gov.
    • 08 Sep 2008 Preliminary results from the fourth cohort reported in a Pharmasset media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top